Riskpilot← Back to searchSign inGet full accessBELLEVACC AS
ASActiveOrg 914753538Høgskoleveien 8, 1433 ÅsManufacture of pharmaceutical preparations · NACE 2120Est. 20150 employees
Revenue 2024
NOK 0
EBITDA margin
—
-891% vs 2023
Equity ratio
89.6%
Financial strength
Net profit 2024
NOK -1,4M
-896% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -1,4M | -891% |
| Net profit | NOK -1,4M | -896% |
| Total assets | NOK 2,3M | -35% |
| Equity | NOK 2M | -40% |
| Employees | 0 | — |
Legal name
BELLEVACC AS
Org number
914753538
Legal form
Aksjeselskap
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
6. januar 2015
Share capital
NOK 175 268
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Utvikle og selge legemidler.
Address
Høgskoleveien 8, 1433 Ås
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 250 | 149 | 100 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −24 | −89 | −9 | −24 | −110 | −60 | −86 | −65 | −138 | −1 363 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −24 | −89 | −9 | −24 | −110 | −60 | −86 | −65 | −138 | −1 363 |
| Net financials | 0 | 0 | −7 | −6 | −6 | −6 | 0 | 0 | 0 | −7 |
| Profit before tax | −24 | −89 | −15 | −30 | −116 | −66 | −86 | −65 | −138 | −1 370 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −24 | −89 | −15 | −30 | −116 | −66 | −86 | −65 | −138 | −1 370 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 24 | 6 | 0 | 33 | 162 | 43 | 180 | 59 | 3 510 | 2 280 |
| Equity | 6 | −84 | −99 | −70 | −186 | −252 | 116 | 51 | 3 414 | 2 044 |
| Long-term debt | 0 | 0 | 0 | 102 | 108 | 115 | 0 | 0 | 0 | 0 |
| Short-term debt | 19 | 90 | 100 | 0 | 239 | 181 | 63 | 8 | 97 | 236 |
| Total debt | 19 | 90 | 100 | 102 | 348 | 296 | 63 | 8 | 97 | 236 |
EBITDA margin
-136309600.0%
This company
15.8%
Market median
-862719087% vs market
20152024
Equity ratio
89.6%
This company
38.2%
Market median
+135% vs market
20152024
Return on equity
-67.0%
This company
18.4%
Market median
-464% vs market
20152024
Net profit margin
-136994700.0%
This company
8.1%
Market median
-1691292693% vs market
20152024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152024
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
20152024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2014-12-18 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TL Contact Person | Contact Person | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2018 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2023 | — | — | |
| Chairman | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Previwo As | Company | 75.9% | 75.9% | 2024 |
Kjeller Innovasjon As | Company | 31.8% | 31.8% | 2022 |
Henning Sørum Holding As | Company | 24.1% | 24.1% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Henning Sørum Holding As
BELLEVACC AS Board members of BELLEVACC AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Terje Landsgård | Contact Person | 0 companies |
| Nils Haga | Chairman | 0 companies |
| Kira Salonius | Board of Directors | 0 companies |
| Hallvard Peter Bogh Muri | Chairman | 0 companies |
| Rune Henning Sørum | Board of Directors | 0 companies |
| Lars Kristian Bredahl | Board of Directors | 0 companies |
| Mathias Lange Dokkan-Thorsen | Board of Directors | 0 companies |
| Hege Tjørsvaag Brattebø | Chairman | 0 companies |
| Aud Kari Fauske | Chairman | 0 companies |